EGFR and melanoma: BRAF-mutant COADREAD (7.6% of patients) presents a similar problem in that BRAF inhibitor monotherapy is ineffective unlike in BRAF-mutant melanoma and that triple drug combination targeting the EGFR, MAPK, and PI3K pathway has shown more positive results.